National Ovarian Cancer Early Detection Program (NOCEDP)
"Every day that passes without a cure means the suffering and death of countless women," says David Fishman, MD, Director of the NOCEDP at Mount Sinai. "Our number one priority is to help save women's lives. There's nothing more rewarding than that."
Mount Sinai leads an international clinical and scientific effort to identify new screening methods for the early detection of epithelial ovarian cancer in asymptomatic high-risk women. Established in 1999, we are the only NOCEDP site where gynecologic oncologists are working so closely with genetic counselors.
The hallmark of the program is the coordinated, multidisciplinary services we provide during each comprehensive clinic visit including evaluations by board certified specialists in cancer genetics, gynecologic oncology, ultrasound, and psychology. Participants receive a consultation with a board certified genetic counselor that reviews the family history of cancer in detail and provides an estimate of the likelihood of hereditary susceptibility. We also provide women and their families the opportunity to discuss the numerous and complicated issues surrounding genetic testing. Women who participate in the program return every six months for follow-up, but remain with their own gynecologists for routine care.
As a state-of-the-art clinical research program, the NOCEDP has achieved international recognition for scientific insights regarding the genetics, biology and mechanisms of ovarian cancer. It is our goal to translate the information we learn into new methods for both the identification of at-risk women, as well as early detection of early stage disease and treatment of ovarian cancer. These studies, if successful, will have a significant impact on lowering the mortality rate associated with ovarian cancer and significantly improve women's healthcare.
Ovarian cancer is the fifth leading cause of cancer death among U.S. women and has the highest mortality rate of all gynecologic cancers. The majority of women continue to be diagnosed when the disease has reached an advanced stage and the overall survival rate for women is poor. However, if ovarian cancer is detected early, the survival rate is more than 90%, requires less radical operations, and may not require adjuvant chemotherapy.
Ultimately we hope that the work of the NOCEDP will lead to an affordable ovarian cancer screening test that can be used anywhere in the world.
If you would like information about the Ovarian Cancer Early Detection Program at Mount Sinai, please contact David Fishman, MD at (212) 427-9898 or email him at firstname.lastname@example.org.
David Fishman, MD discusses the importance of Mount Sinai's Ovarian Cancer Early Detection Program.
David Fishman talks about the importance of early detection of Ovarian Cancer. View Now